Compounds Which Selectively Modulate The CB2 Receptor

A compound of the formula (I)

• wherein:
• Het is a 5-membered heteroaryl ring optionally substituted by C1-5 alkyl;
• R1 is C1-10 alkyl, C1-10 alkoxy, C3-10 cycloalkyl, 3-10 membered saturated heterocyclic ring, 5-10 membered mono or bicyclic heteroaryl ring or phenyl each optionally independently substituted with 1-3 substituents chosen from C1-8 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkylC1-5 alkyl, C1-4 alkylsulfonyl, C1-4 acyl, oxo, cyano, phenyl, hydroxyl and halogen;
• R2 and R3 are C1-C4 alkyl or hydrogen with the proviso that both R2 and R3 cannot be hydrogen;
• or R2 and R3 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocyclic ring;
• R4 is hydrogen or methyl;
• R5 is chosen from
• or R5 is a 3-10 membered saturated heterocyclic ring optionally substituted with 1-3 C1-4 alkyl;
• m is 0, 1, 2 or 3;
• each R6 is independently hydrogen, C1-6 alkyl, 3-10 membered saturated heterocyclic ring, aryl, benzyl or —(CH2)1-3—O—(CH2)0-1—X wherein X is aryl or CH3 each heterocyclic, benzyl or aryl ring is optionally substituted by one or more C1-4 alkyl, C1-4 alkoxy or halogen;
• wherein R7 and R8 are each independently hydrogen or C1-4 alkyl with the proviso that both R7 and R8 cannot be hydrogen, and wherein R7 and R8 optionally can cyclize to form a C3-7 cycloalkyl ring;
• R9 is C1-4 alkyl which replaces a methylene hydrogen on —(CH2)n— or is absent;
• n is 0, 1 or 2;
• wherein any carbon atom on the formula (I) or any R substituent listed above is optionally partially or fully halogenated where possible;
• or a pharmaceutically acceptable salt thereof